Compare SCLX & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | NEPH |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.3M | 60.0M |
| IPO Year | N/A | 2004 |
| Metric | SCLX | NEPH |
|---|---|---|
| Price | $16.55 | $5.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 120.8K | 74.6K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | ★ $40,360,000.00 | $17,930,000.00 |
| Revenue This Year | N/A | $33.32 |
| Revenue Next Year | $749.70 | $12.27 |
| P/E Ratio | ★ N/A | $36.15 |
| Revenue Growth | N/A | ★ 32.36 |
| 52 Week Low | $3.60 | $1.39 |
| 52 Week High | $34.27 | $6.42 |
| Indicator | SCLX | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.66 | 48.33 |
| Support Level | $18.34 | $4.83 |
| Resistance Level | $20.62 | $5.97 |
| Average True Range (ATR) | 1.46 | 0.63 |
| MACD | -0.39 | -0.03 |
| Stochastic Oscillator | 3.10 | 28.93 |
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.